The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 300 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.
Looking for a particular Cell and Gene Therapy Catapult employee's phone or email?
Cell and Gene Therapy Catapult Questions
The Cell and Gene Therapy Catapult annual revenue was $33.6 million in 2026.
Matthew Durdy is the Chief Executive of Cell and Gene Therapy Catapult.
300 people are employed at Cell and Gene Therapy Catapult.
The NAICS codes for Cell and Gene Therapy Catapult are [51, 518].
The SIC codes for Cell and Gene Therapy Catapult are [73, 737].
Top Cell and Gene Therapy Catapult Employees
-
Matthew Durdy
Chief Executive at Cell and Gene Therapy Catapult
London, England, GB14 -
Nick S
CTO at Cell and Gene Therapy Catapult
Bristol, England, GB15 -
21
-
44
-
11
Related Companies
